Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoViricides Drug Effectiveness Confirmed against Rabies and Influenzas

Abstract:
Survival Superior to Standard Antibody Treatment In Rabies-infected Animals

NanoViricides Drug Effectiveness Confirmed against Rabies and Influenzas

WEST HAVEN, CT | Posted on November 12th, 2007

NanoViricides, Inc. (OTC BB: NNVC.OB) said that in a confirmatory study, their nanoviricide™ drug candidates exhibited a consistent 20% to 30% survival in the test animals. In contrast, a commercial anti-rabies antibody produced 0% or no survival, as in the previous study. These results clearly demonstrate the superiority of the multi-valent targeting nanoviricides technology over antibody therapy. Scientists at the National Institute of Hygiene and Epidemiology in Hanoi, Vietnam performed the studies.

"Scientific data of this type provides further evidence of the effectiveness of these novel nanomedicines," said Dr. Eugene Seymour, the Company's CEO. Consistent and reproducible repeat results have also been reported against common influenza (H1N1) using different production batches in animal studies previously performed by the Company.

"The fact that these repeat rabies studies were done in a premier independent government laboratory is extremely important to us," said CEO Eugene Seymour, MD, adding, "this assures that no inherent bias influenced the outcome. This is of particular importance with any new technology on the cutting-edge of medical treatments. Our confirmatory strategy will be the same with the Ebola and Dengue work that is proceeding in two US government research laboratories."

An estimated 10 million people receive post-exposure treatments each year after being exposed to rabies-suspect animals. About 30,000 people in the United States receive both pre-and post exposure prophylaxis every year, at a cost of over $1000 per treatment course. The annual number of deaths worldwide caused by rabies is estimated to be 55,000, mostly in rural areas of Africa and Asia, according to a recent World Health Organization report.

Rabies, a uniformly fatal disease found primarily in Africa and Southeast Asia, had never before been successfully treated with drugs.

There are currently no FDA-approved treatment options for rabies once symptoms develop. In addition, the Company believes that significantly increased survival rate of these lethally infected animals is possible in the dose-ranging studies to follow.

####

About NanoViricides, Inc.
NanoViricides, Inc. ( http://www.nanoviricides.com ) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

For more information, please click here

Contacts:
NanoViricides, Inc.
Amanda Schuon
310-550-7200

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014

PAM-XIAMEN Offers UV LED wafer April 15th, 2014

Nanocrystalline cellulose modified into an efficient viral inhibitor April 15th, 2014

Targeting cancer with a triple threat: MIT chemists design nanoparticles that can deliver three cancer drugs at a time April 15th, 2014

Announcements

Relieving electric vehicle range anxiety with improved batteries: Lithium-sulfur batteries last longer with nanomaterial-packed cathode April 16th, 2014

Aerotech X-Y ball-screw stage for economical high performance Planar positioning April 16th, 2014

Energy Research Facility Construction Project at Brookhaven Lab Wins U.S. Energy Secretary's Achievement Award April 16th, 2014

Malvern reports on the publication of the 1000th peer-reviewed paper to cite NanoSight’s Nanoparticle Tracking Analysis, NTA April 16th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE